The patent protection period in India for semaglutide, the active ingredient in Ozempic developed by the Denmark-based healthcare company Novo Nordisk, has expired. Following this development, at least four major India-based pharmaceutical manufacturers have taken action to launch generic versions of the drug, which is highly sought after globally for the treatment of obesity and type 2 diabetes.
Four major companies race for generic production
With the expiration of the patent, India’s leading pharmaceutical firms have accelerated their licensing processes for generic production. Companies including Sun Pharmaceutical, Dr. Reddy’s Laboratories, and Cipla, which operate on a global scale, are expected to bring locally produced semaglutide-based drugs to market shortly.
Industry representatives predict that the introduction of generic versions will overcome the current global supply bottlenecks and high-cost issues.
Significant drop in treatment costs anticipated
Branded drugs containing the active ingredient semaglutide, such as Ozempic, Wegovy, and Rybelsus produced by Novo Nordisk, have faced accessibility challenges due to their high prices. The start of generic production in India aims to significantly drive down the costs of these treatments.
Experts emphasize that the expected price reduction will facilitate access to treatment for patients with type 2 diabetes and obesity, particularly in developing countries.
Branded semaglutide drugs and their uses
Semaglutide works by mimicking the glucagon-like peptide-1 (GLP-1) hormone, which regulates blood sugar and creates a feeling of fullness. Currently, three main products stand out in the market:
Ozempic: A weekly injection approved for the treatment of type 2 diabetes.
Wegovy: A higher-dose version specifically formulated for weight management and obesity treatment.
Rybelsus: The only oral tablet form of semaglutide.
A new era of competition in the pharmaceutical market
India’s generic drug move is poised to shift the balance in the global pharmaceutical market. Experts point out that the genericization of semaglutide could also create price pressure on other weight-loss drugs, such as those based on tirzepatide produced by US-based rivals like Eli Lilly. With generics entering the market, the cost barrier in the fight against obesity is expected to break, opening a new chapter in global health policies.